- Home
- BHV vs BCDA Comparison
BHV vs BCDA Comparison
Compare BHV & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHV | BCDA |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 14.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BHV | BCDA |
|---|---|---|
| Price | $10.64 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 3.5K | ★ 71.3K |
| Earning Date | 01-01-0001 | 03-25-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.85 | $1.00 |
| 52 Week High | $12.08 | $3.20 |
Technical Indicators
Market Signals| Indicator | BHV | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 37.85 |
| Support Level | $10.69 | $1.10 |
| Resistance Level | $10.81 | $1.33 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 42.37 | 20.00 |
Price Performance
Historical ComparisonAbout BHV BlackRock Virginia Municipal Bond Trust
Blackrock Virginia Municipal Bond Trust is a perpetual closed-end municipal bond fund. Its objective is to provide current income exempt from regular Federal income taxes and Virginia personal income taxes.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).